These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 26407380)

  • 1. The direct cost of intravenous insulin infusions to the NHS in England and Wales.
    Rajendran R; Scott A; Rayman G
    Clin Med (Lond); 2015 Aug; 15(4):330-3. PubMed ID: 26407380
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bariatric surgery for patients with type 2 diabetes mellitus requiring insulin: Clinical outcome and cost-effectiveness analyses.
    McGlone ER; Carey I; Veličković V; Chana P; Mahawar K; Batterham RL; Hopkins J; Walton P; Kinsman R; Byrne J; Somers S; Kerrigan D; Menon V; Borg C; Ahmed A; Sgromo B; Cheruvu C; Bano G; Leonard C; Thom H; le Roux CW; Reddy M; Welbourn R; Small P; Khan OA
    PLoS Med; 2020 Dec; 17(12):e1003228. PubMed ID: 33285553
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Continuous subcutaneous insulin infusion versus multiple daily injections in children and young people at diagnosis of type 1 diabetes: the SCIPI RCT.
    Blair J; McKay A; Ridyard C; Thornborough K; Bedson E; Peak M; Didi M; Annan F; Gregory JW; Hughes D; Gamble C
    Health Technol Assess; 2018 Aug; 22(42):1-112. PubMed ID: 30109847
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Healthcare resource utilization and related financial costs associated with glucose lowering with either exenatide or basal insulin: A retrospective cohort study.
    Holden SE; Morgan CL; Qiao Q; Jenkins-Jones S; Berni ER; Currie CJ
    Diabetes Obes Metab; 2017 Aug; 19(8):1097-1105. PubMed ID: 28218819
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Human insulin vs. analogs. What is the cost of supplementary insulin therapy?].
    Lundershausen R; Potthoff F; Häuser C; Kaiser M; Münscher C
    MMW Fortschr Med; 2006 Nov; 148(45):42. PubMed ID: 17615748
    [No Abstract]   [Full Text] [Related]  

  • 6. Budget impact of continuous subcutaneous insulin infusion therapy in patients with type 1 diabetes who experience severe recurrent hypoglycemic episodes in Spain.
    Giménez M; Elías I; Álvarez M; Quirós C; Conget I
    Endocrinol Diabetes Nutr; 2017; 64(7):377-383. PubMed ID: 28745609
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The excess cost of acute exacerbations of chronic bronchitis in patients aged 45 and older in England and Wales.
    McGuire A; Irwin DE; Fenn P; Gray A; Anderson P; Lovering A; MacGowan A
    Value Health; 2001; 4(5):370-5. PubMed ID: 11705127
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resource utilization with insulin pump therapy for type 2 diabetes mellitus.
    Lynch PM; Riedel AA; Samant N; Fan Y; Peoples T; Levinson J; Lee SW
    Am J Manag Care; 2010; 16(12):892-6. PubMed ID: 21348559
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is the current standard of care leading to cost-effective outcomes for patients with type 2 diabetes requiring insulin? A long-term health economic analysis for the UK.
    Valentine WJ; Curtis BH; Pollock RF; Van Brunt K; Paczkowski R; Brändle M; Boye KS; Kendall DM
    Diabetes Res Clin Pract; 2015 Jul; 109(1):95-103. PubMed ID: 25989713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparing insulin vials to pens--comparison of charges, not healthcare benefits.
    Thethi TK
    J Med Econ; 2013 Oct; 16(10):1228-30. PubMed ID: 23926888
    [No Abstract]   [Full Text] [Related]  

  • 11. Effect of V-Go Versus Multiple Daily Injections on Glycemic Control, Insulin Use, and Diabetes Medication Costs Among Individuals with Type 2 Diabetes Mellitus.
    Raval AD; Nguyen MH; Zhou S; Grabner M; Barron J; Quimbo R
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1111-1123. PubMed ID: 31556817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of continuous subcutaneous insulin infusion in people with type 2 diabetes in the Netherlands.
    Roze S; Duteil E; Smith-Palmer J; de Portu S; Valentine W; de Brouwer BF; Reznik Y; de Valk HW
    J Med Econ; 2016 Aug; 19(8):742-9. PubMed ID: 26985982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
    Plosker GL; Figgitt DP
    Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [BOT with insulin glargine versus BOT with insulin detemir: comparison of treatment costs in type 2 diabetes based on the results of the insulin glargine (Lantus) versus insulin detemir (Levemir) Treat-To-Target (L2T3) study from the German Statutory Health Insurance perspective].
    Schädlich PK; Koltermann KC; Dippel FW; Hagenmeyer EG; Häussler B
    MMW Fortschr Med; 2010 Oct; 152 Suppl 3():89-95. PubMed ID: 21595152
    [No Abstract]   [Full Text] [Related]  

  • 15. Cost comparison of insulin glargine with insulin detemir in a basal-bolus regime with mealtime insulin aspart in type 2 diabetes in Germany.
    Pscherer S; Dietrich ES; Dippel FW; Neilson AR
    Ger Med Sci; 2010 Aug; 8():. PubMed ID: 20725588
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dispensing patterns and financial costs of glucose-lowering therapies in the UK from 2000 to 2008.
    Currie CJ; Peters JR; Evans M
    Diabet Med; 2010 Jul; 27(7):744-52. PubMed ID: 20636954
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the cost effectiveness of exenatide versus insulin glargine in patients with sub-optimally controlled type 2 diabetes in the United Kingdom.
    Woehl A; Evans M; Tetlow AP; McEwan P
    Cardiovasc Diabetol; 2008 Aug; 7():24. PubMed ID: 18694484
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health Outcomes Associated with Initiation of Basal Insulin After 1, 2, or ≥ 3 Oral Antidiabetes Drug(s) Among Managed Care Patients with Type 2 Diabetes.
    Levin PA; Zhou S; Gill J; Wei W
    J Manag Care Spec Pharm; 2015 Dec; 21(12):1172-81. PubMed ID: 26679966
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Long-term Cost-effectiveness of Insulin Degludec Versus Insulin Glargine U100 in the UK: Evidence from the Basal-bolus Subgroup of the DEVOTE Trial (DEVOTE 16).
    Pollock RF; Valentine WJ; Marso SP; Andersen A; Gundgaard J; Hallén N; Tutkunkardas D; Magnuson EA; Buse JB;
    Appl Health Econ Health Policy; 2019 Oct; 17(5):615-627. PubMed ID: 31264138
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Insulin: standard therapy following oral hypoglycaemic failure in type 2 diabetes?
    English P
    Br J Hosp Med (Lond); 2013 Apr; 74(4):192-7. PubMed ID: 23571388
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.